AS
Altshuler Shaham Portfolio holdings
AUM
$3.14B
1-Year Return
24.55%
This Quarter Return
-2.28%
1 Year Return
+24.55%
3 Year Return
+51.84%
5 Year Return
+71.45%
10 Year Return
–
AUM
$13.6B
AUM Growth
+$222M
(+1.7%)
Cap. Flow
-$1.8B
Cap. Flow
% of AUM
-13.16%
Top 10 Holdings %
Top 10 Hldgs %
54.62%
Holding
698
New
97
Increased
150
Reduced
154
Closed
203
Top Buys
| 1 |
KraneShares CSI China Internet ETF
KWEB
|
+$890M |
| 2 |
Elevance Health
ELV
|
+$381M |
| 3 |
Bank of America
BAC
|
+$330M |
| 4 |
JPMorgan Chase
JPM
|
+$329M |
| 5 |
Wells Fargo
WFC
|
+$309M |
Top Sells
| 1 |
Microsoft
MSFT
|
+$2.12B |
| 2 |
Pfizer
PFE
|
+$757M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$414M |
| 4 |
Alibaba
BABA
|
+$322M |
| 5 |
TSMC
TSM
|
+$319M |
Sector Composition
| 1 | Technology | 36.3% |
| 2 | Financials | 19.01% |
| 3 | Healthcare | 7.36% |
| 4 | Communication Services | 5.95% |
| 5 | Consumer Staples | 5.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
401
Boston Scientific
BSX
$160B
| $49K | ﹤0.01% |
+1,117
| New | +$49K |
|
402
Chemed
CHE
$6.76B
| $49K | ﹤0.01% |
105
+20
| +24% | +$9.33K |
|
403
Henry Schein
HSIC
$8.21B
| $49K | ﹤0.01% |
640
+104
| +19% | +$7.96K |
|
404
Masimo
MASI
$8.08B
| $49K | ﹤0.01% |
+181
| New | +$49K |
|
405
Prestige Consumer Healthcare
PBH
$3.24B
| $49K | ﹤0.01% |
873
+43
| +5% | +$2.41K |
|
|
HSKA
406
DELISTED
Heska Corp
HSKA
| $49K | ﹤0.01% |
+187
| New | +$49K |
|
407
Maximus
MMS
$4.98B
| $48K | ﹤0.01% |
572
+112
| +24% | +$9.4K |
|
408
Stryker
SYK
$150B
| $48K | ﹤0.01% |
181
-67
| -27% | -$17.8K |
|
409
Upstart Holdings
UPST
$6.56B
| $48K | ﹤0.01% |
+151
| New | +$48K |
|
410
Align Technology
ALGN
$9.92B
| $47K | ﹤0.01% |
+70
| New | +$47K |
|
411
Capital One
COF
$141B
| $47K | ﹤0.01% |
289
-1,452
| -83% | -$236K |
|
412
Medtronic
MDT
$119B
| $47K | ﹤0.01% |
+373
| New | +$47K |
|
413
Omnicell
OMCL
$1.49B
| $47K | ﹤0.01% |
317
-464
| -59% | -$68.8K |
|
414
Surmodics
SRDX
$471M
| $47K | ﹤0.01% |
832
-1,280
| -61% | -$72.3K |
|
415
Usana Health Sciences
USNA
$565M
| $47K | ﹤0.01% |
508
+112
| +28% | +$10.4K |
|
416
Abbott
ABT
$230B
| $46K | ﹤0.01% |
+389
| New | +$46K |
|
417
AngioDynamics
ANGO
$443M
| $46K | ﹤0.01% |
1,767
+43
| +2% | +$1.12K |
|
418
AtriCure
ATRC
$1.79B
| $46K | ﹤0.01% |
657
-809
| -55% | -$56.6K |
|
419
Bio-Rad Laboratories Class A
BIO
$7.86B
| $46K | ﹤0.01% |
+61
| New | +$46K |
|
420
Bristol-Myers Squibb
BMY
$95.1B
| $46K | ﹤0.01% |
+765
| New | +$46K |
|
421
Cooper Companies
COO
$13.7B
| $46K | ﹤0.01% |
+440
| New | +$46K |
|
|
DFS
422
DELISTED
Discover Financial Services
DFS
| $46K | ﹤0.01% |
369
-14
| -4% | -$1.75K |
|
423
The Joint Corp
JYNT
$163M
| $46K | ﹤0.01% |
468
-90
| -16% | -$8.85K |
|
424
LeMaitre Vascular
LMAT
$2.2B
| $46K | ﹤0.01% |
858
+65
| +8% | +$3.49K |
|
425
Veeva Systems
VEEV
$46.3B
| $46K | ﹤0.01% |
+158
| New | +$46K |
|